148 related articles for article (PubMed ID: 28055969)
1. TMPRSS2-ERG fusion promotes prostate cancer metastases in bone.
Deplus R; Delliaux C; Marchand N; Flourens A; Vanpouille N; Leroy X; de Launoit Y; Duterque-Coquillaud M
Oncotarget; 2017 Feb; 8(7):11827-11840. PubMed ID: 28055969
[TBL] [Abstract][Full Text] [Related]
2. Effect of nonsteroidal anti-inflammatory drugs (aspirin and naproxen) on inflammation-associated proteomic profiles in mouse plasma and prostate during TMPRSS2-ERG (fusion)-driven prostate carcinogenesis.
Prasad RR; Mishra N; Kant R; Fox JT; Shoemaker RH; Agarwal C; Raina K; Agarwal R
Mol Carcinog; 2024 Jun; 63(6):1188-1204. PubMed ID: 38506376
[TBL] [Abstract][Full Text] [Related]
3. Extensive germline-somatic interplay contributes to prostate cancer progression through HNF1B co-option of TMPRSS2-ERG.
Giannareas N; Zhang Q; Yang X; Na R; Tian Y; Yang Y; Ruan X; Huang D; Yang X; Wang C; Zhang P; Manninen A; Wang L; Wei GH
Nat Commun; 2022 Nov; 13(1):7320. PubMed ID: 36443337
[TBL] [Abstract][Full Text] [Related]
4. Gain-of-function mutant p53 together with ERG proto-oncogene drive prostate cancer by beta-catenin activation and pyrimidine synthesis.
Ding D; Blee AM; Zhang J; Pan Y; Becker NA; Maher LJ; Jimenez R; Wang L; Huang H
Nat Commun; 2023 Aug; 14(1):4671. PubMed ID: 37537199
[TBL] [Abstract][Full Text] [Related]
5. The bone microenvironment invigorates metastatic seeds for further dissemination.
Zhang W; Bado IL; Hu J; Wan YW; Wu L; Wang H; Gao Y; Jeong HH; Xu Z; Hao X; Lege BM; Al-Ouran R; Li L; Li J; Yu L; Singh S; Lo HC; Niu M; Liu J; Jiang W; Li Y; Wong STC; Cheng C; Liu Z; Zhang XH
Cell; 2021 Apr; 184(9):2471-2486.e20. PubMed ID: 33878291
[TBL] [Abstract][Full Text] [Related]
6. Mapping Isoform Abundance and Interactome of the Endogenous TMPRSS2-ERG Fusion Protein by Orthogonal Immunoprecipitation-Mass Spectrometry Assays.
Fu Z; Rais Y; Bismar TA; Hyndman ME; Le XC; Drabovich AP
Mol Cell Proteomics; 2021; 20():100075. PubMed ID: 33771697
[TBL] [Abstract][Full Text] [Related]
7. Differential Effect of Non-Steroidal Anti-Inflammatory Drugs Aspirin and Naproxen against
Raina K; Kandhari K; Kant R; Prasad RR; Mishra N; Maurya AK; Fox JT; Sei S; Shoemaker RH; Bosland MC; Maroni P; Agarwal C; Agarwal R
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894421
[TBL] [Abstract][Full Text] [Related]
8. Cadherin-11 promotes the metastasis of prostate cancer cells to bone.
Chu K; Cheng CJ; Ye X; Lee YC; Zurita AJ; Chen DT; Yu-Lee LY; Zhang S; Yeh ET; Hu MC; Logothetis CJ; Lin SH
Mol Cancer Res; 2008 Aug; 6(8):1259-67. PubMed ID: 18708358
[TBL] [Abstract][Full Text] [Related]
9. DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer.
Liu W
Asian J Androl; 2016; 18(4):533-42. PubMed ID: 26975494
[TBL] [Abstract][Full Text] [Related]
10. Plectin is a regulator of prostate cancer growth and metastasis.
Buckup M; Rice MA; Hsu EC; Garcia-Marques F; Liu S; Aslan M; Bermudez A; Huang J; Pitteri SJ; Stoyanova T
Oncogene; 2021 Jan; 40(3):663-676. PubMed ID: 33219316
[TBL] [Abstract][Full Text] [Related]
11. Optimization of prostate cancer cell detection using multiplex tyramide signal amplification.
Roy S; Axelrod HD; Valkenburg KC; Amend S; Pienta KJ
J Cell Biochem; 2019 Apr; 120(4):4804-4812. PubMed ID: 30390333
[TBL] [Abstract][Full Text] [Related]
12. Impact TMPRSS2-ERG Molecular Subtype on Prostate Cancer Recurrence.
Kobelyatskaya AA; Pudova EA; Snezhkina AV; Fedorova MS; Pavlov VS; Guvatova ZG; Savvateeva MV; Melnikova NV; Dmitriev AA; Trofimov DY; Sukhikh GT; Nyushko KM; Alekseev BY; Razin SV; Krasnov GS; Kudryavtseva AV
Life (Basel); 2021 Jun; 11(6):. PubMed ID: 34205581
[TBL] [Abstract][Full Text] [Related]
13.
Zhang Z; Chen W; Sun M; Aalders T; Verhaegh GW; Kouwer PHJ
ACS Appl Mater Interfaces; 2024 May; 16(20):25773-25787. PubMed ID: 38739686
[TBL] [Abstract][Full Text] [Related]
14. Comparison of ex vivo bioluminescence imaging, Alu-qPCR and histology for the quantification of spontaneous lung and bone metastases in subcutaneous xenograft mouse models.
Haider MT; Freytag V; Krause L; Spethmann T; Gosau T; Beine MC; Knies C; Schröder-Schwarz J; Horn M; Riecken K; Lange T
Clin Exp Metastasis; 2024 Apr; 41(2):103-115. PubMed ID: 38353934
[TBL] [Abstract][Full Text] [Related]
15. RNA-seq Based Transcription Characterization of Fusion Breakpoints as a Potential Estimator for Its Oncogenic Potential.
Gu JL; Chukhman M; Lu Y; Liu C; Liu SY; Lu H
Biomed Res Int; 2017; 2017():9829175. PubMed ID: 29181411
[TBL] [Abstract][Full Text] [Related]
16. Ecological paradigms to understand the dynamics of metastasis.
Amend SR; Roy S; Brown JS; Pienta KJ
Cancer Lett; 2016 Sep; 380(1):237-42. PubMed ID: 26458994
[TBL] [Abstract][Full Text] [Related]
17.
Bauer S; Ratz L; Heckmann-Nötzel D; Kaczorowski A; Hohenfellner M; Kristiansen G; Duensing S; Altevogt P; Klauck SM; Sültmann H
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33669024
[TBL] [Abstract][Full Text] [Related]
18. An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer.
Das R; Sjöström M; Shrestha R; Yogodzinski C; Egusa EA; Chesner LN; Chen WS; Chou J; Dang DK; Swinderman JT; Ge A; Hua JT; Kabir S; Quigley DA; Small EJ; Ashworth A; Feng FY; Gilbert LA
Nat Commun; 2021 Jul; 12(1):4601. PubMed ID: 34326322
[TBL] [Abstract][Full Text] [Related]
19. Steps in prostate cancer progression that lead to bone metastasis.
Jin JK; Dayyani F; Gallick GE
Int J Cancer; 2011 Jun; 128(11):2545-61. PubMed ID: 21365645
[TBL] [Abstract][Full Text] [Related]
20. Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples.
Olivan M; Garcia M; Suárez L; Guiu M; Gros L; Méndez O; Rigau M; Reventós J; Segura MF; de Torres I; Planas J; de la Cruz X; Gomis RR; Morote J; Rodríguez-Barrueco R; Santamaria A
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
